OTLK OUTLOOK THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, OUTLOOK THERAPEUTICS INC reported revenue of n/a, net income of −$20.3M and diluted EPS of −$0.15; for the fiscal year ended September 2025 revenue was $1.41M.
OTLK annual revenue and earnings
- Fiscal year ended Sep 2025: revenue $1.41M, gross profit $57.2K, operating income −$67.1M, net income −$62.4M (margin -4416.2%), EPS −$1.79
- Fiscal year ended Sep 2024: revenue n/a, gross profit n/a, operating income −$71.7M, net income −$75.4M (margin n/a), EPS −$4.06
- Fiscal year ended Sep 2023: revenue n/a, gross profit n/a, operating income −$53.1M, net income −$59.0M (margin n/a), EPS −$4.72
- Fiscal year ended Sep 2022: revenue n/a, gross profit n/a, operating income −$63.1M, net income −$66.1M (margin n/a), EPS −$0.31
- Fiscal year ended Sep 2021: revenue n/a, gross profit n/a, operating income −$51.7M, net income −$53.2M (margin n/a), EPS −$0.35
OTLK quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$20.3M, EPS −$0.15
- Quarter ended Mar 31, 2026: revenue n/a, net income −$4.45M, EPS −$0.05
- Quarter ended Dec 31, 2025: revenue n/a, net income −$23.1M, EPS −$0.38
- Quarter ended Sep 30, 2025 (from the annual report): revenue n/a, net income −$13.3M, EPS −$0.46
- Quarter ended Jun 30, 2025: revenue $1.51M, net income −$20.2M, EPS −$0.55
- Quarter ended Mar 31, 2025: revenue n/a, net income −$46.4M, EPS −$1.50
- Quarter ended Dec 31, 2024: revenue n/a, net income $17.4M, EPS $0.72
- Quarter ended Sep 30, 2024 (from the annual report): revenue n/a, net income $5.69M, EPS $5.70
- Quarter ended Jun 30, 2024: revenue n/a, net income $44.4M, EPS −$0.89
- Quarter ended Mar 31, 2024: revenue n/a, net income −$114M, EPS −$8.01
- Quarter ended Dec 31, 2023: revenue n/a, net income −$11.2M, EPS −$0.86
- Quarter ended Sep 30, 2023 (from the annual report): revenue n/a, net income −$13.0M, EPS −$2.51
- Quarter ended Jun 30, 2023: revenue n/a, net income −$20.7M, EPS −$1.61
- Quarter ended Mar 31, 2023: revenue n/a, net income −$6.65M, EPS −$0.52
- Quarter ended Dec 31, 2022: revenue n/a, net income −$18.7M, EPS −$0.08
- Quarter ended Sep 30, 2022 (from the annual report): revenue n/a, net income −$14.3M, EPS −$0.06
- Quarter ended Jun 30, 2022: revenue n/a, net income −$17.5M, EPS −$0.08
- Quarter ended Mar 31, 2022: revenue n/a, net income −$19.7M, EPS −$0.09
- Quarter ended Dec 31, 2021: revenue n/a, net income −$14.5M, EPS −$0.08
- Quarter ended Jun 30, 2021: revenue n/a, net income −$12.2M, EPS −$0.07
OTLK cash flow, buybacks and dividends
- Fiscal year ended Sep 2025: operating cash flow −$51.8M, share buybacks n/a
- Fiscal year ended Sep 2024: operating cash flow −$68.8M, share buybacks n/a
- Fiscal year ended Sep 2023: operating cash flow −$43.0M, share buybacks n/a
- Fiscal year ended Sep 2022: operating cash flow −$56.7M, share buybacks n/a
- Fiscal year ended Sep 2021: operating cash flow −$54.3M, share buybacks n/a
OTLK balance sheet
- Jun 30, 2026: cash $11.2M, total assets $26.2M, total liabilities $36.6M, shareholders' equity −$10.4M
- Mar 31, 2026: cash $7.75M, total assets $21.9M, total liabilities $50.9M, shareholders' equity −$29.0M
- Dec 31, 2025: cash $8.68M, total assets $18.2M, total liabilities $56.8M, shareholders' equity −$38.5M
- Sep 30, 2025: cash $8.08M, total assets $18.6M, total liabilities $50.8M, shareholders' equity −$32.2M
- Jun 30, 2025: cash $8.90M, total assets $22.4M, total liabilities $59.6M, shareholders' equity −$37.2M
- Mar 31, 2025: cash $7.56M, total assets $19.1M, total liabilities $51.5M, shareholders' equity −$32.5M
- Dec 31, 2024: cash $5.70M, total assets $17.0M, total liabilities $67.3M, shareholders' equity −$50.3M
- Sep 30, 2024: cash $14.9M, total assets $28.8M, total liabilities $102M, shareholders' equity −$73.1M
What is OTLK's revenue?
OUTLOOK THERAPEUTICS INC reported $1.41M of revenue for the fiscal year ended September 2025.
Is OTLK profitable?
No. OUTLOOK THERAPEUTICS INC lost $61.1M over the last four quarters.
What is OTLK's EPS?
Diluted earnings per share over the last four quarters were −$1.04; −$0.15 in the latest quarter.